Book Now

PROACTIVE PROTECTION AGAINST RSV WITH BEYFORTUS (NIRSEVIMAB)

PROACTIVE PROTECTION AGAINST RSV WITH BEYFORTUS (NIRSEVIMAB)

28/05/2026

RSV (Respiratory Syncytial Virus) is one of the most common causes of bronchiolitis, pneumonia, and severe respiratory failure in newborns and young children, especially during the first months of life when a baby’s immune system is still immature. Currently, the monoclonal antibody Beyfortus (Nirsevimab) is considered an early preventive solution against RSV for newborns and young children.

Unlike traditional vaccines, which require time for the body to develop immunity, Beyfortus provides direct passive immunity, helping babies defend against RSV immediately after administration.

How does Beyfortus work?

Beyfortus is a long-acting IgG1 monoclonal antibody that binds to the RSV F protein, thereby preventing the virus from entering respiratory cells and helping protect children throughout the RSV season — the period when the virus spreads most actively.

Recommended populations

  • Newborns and infants during their first RSV season, including both full-term and preterm infants.

  • Children under 24 months of age at high risk for severe RSV disease, such as those with congenital heart disease, chronic lung disease, or extreme prematurity.

According to international clinical studies, Beyfortus helps:

  • Significantly reduce the risk of RSV-related hospitalization

  • Reduce the risk of intensive care treatment associated with RSV

  • Provide protective efficacy lasting approximately 6 months (equivalent to one RSV season)

High safety profile in young children

Beyfortus has been shown to be safe and well tolerated. Post-injection reactions are generally mild and temporary, such as pain or redness at the injection site, mild fever, or fussiness. In addition, Beyfortus may be administered concurrently with other vaccines as prescribed by a physician.

Reference dosage

  • Children weighing under 5 kg: 50 mg (a single intramuscular injection)

  • Children weighing 5 kg or more: 100 mg (a single intramuscular injection)

  • High-risk children during their second RSV season: 200 mg (two separate 100 mg injections)

The monoclonal antibody Beyfortus (Nirsevimab) from Sanofi (France) is now available at American International Hospital (AIH). We are committed to using high-quality medications with clear origins and to strictly following proper storage protocols and safe immunization procedures for children.

For more detailed information about the RSV preventive monoclonal antibody and the appropriate immunization schedule for each age group, please contact our Hotline at 1900 3399 or message us via https://m.me/aih.com.vn for consultation.

--------------------

AMERICAN INTERNATIONAL HOSPITAL (AIH):
☎ Hotline: 1900 3399 || (028) 3910 9999​
🌏 Website: www.aih.com.vn
📍Address: (Entrance from 199 Nguyen Hoang Street) No.6, Bac Nam 3 Street, Binh Trung Ward, Ho Chi Minh
  • by Admin AIH
  • In News & Events

Leave a comment

Latest News

Our Doctor

Professionals

Kim Tran Quan

Kim Tran Quan

LABORATORY DEPARTMENT

With more than 15 years of experience in medical laboratory science, MSc. Kim Tran Quan currently se...

Tran Thanh Phong

Tran Thanh Phong

DENTAL & MAXILLOFACIAL

With over 20 years of experience in the field of Oral and Maxillofacial Surgery, Dr. Tran Thanh Phon...

Nguyen Duc Trinh

Nguyen Duc Trinh

DENTAL & MAXILLOFACIAL

Dr. Nguyen Duc Trinh is a specialist with over 10 years of clinical experience in the dentomaxillofa...

Mai Vien Phuong

Mai Vien Phuong

GASTROINTESTINAL SURGERY

MSc. Dr. Mai Vien Phuong is an expert in Gastroenterology – Endoscopy with over 15 years of clinical...

Nguyen Quang Dien

Nguyen Quang Dien

INTENSIVE CARE – EMERGENCY

With over 20 years of experience, 1st-degree specialist, Dr. Quang Dien has dedicated many years as...

Huynh Hoang Anh

Huynh Hoang Anh

PEDIATRICS

MD., MSc., Specialist Grade I Huynh Hoang Anh graduated from HCMC University of Medicine and Pharmac...